Functional Viability Profiles of Breast Cancer

被引:122
作者
Brough, Rachel [1 ]
Frankum, Jessica R. [1 ]
Sims, David [1 ]
Mackay, Alan [1 ]
Mendes-Pereira, Ana M. [1 ]
Bajrami, Ilirjana [1 ]
Costa-Cabral, Sara [1 ]
Rafiq, Rumana [1 ]
Ahmad, Amar S. [1 ]
Cerone, Maria Antonietta [1 ]
Natrajan, Rachael [1 ]
Sharpe, Rachel [1 ]
Shiu, Kai-Keen [1 ]
Wetterskog, Daniel [1 ]
Dedes, Konstantine J. [1 ]
Lambros, Maryou B. [1 ]
Rawjee, Teeara [1 ]
Linardopoulos, Spiros [1 ]
Reis-Filho, Jorge S. [1 ]
Turner, Nicholas C. [1 ]
Lord, Christopher J. [1 ]
Ashworth, Alan [1 ]
机构
[1] Inst Canc Res, Breakthrough Breast Canc Res Ctr, Div Breast Canc Res, London SE3 6JB, England
关键词
GENE-EXPRESSION; MUTANT-CELLS; PTEN; KINASE; MUTATIONS; THERAPY; IDENTIFICATION; INSTABILITY; DEFICIENCY; CARCINOMAS;
D O I
10.1158/2159-8290.CD-11-0107
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The design of targeted therapeutic strategies for cancer has largely been driven by the identification of tumor-specific genetic changes. However, the large number of genetic alterations present in tumor cells means that it is difficult to discriminate between genes that are critical for maintaining the disease state and those that are merely coincidental. Even when critical genes can be identified, directly targeting these is often challenging, meaning that alternative strategies such as exploiting synthetic lethality may be beneficial. To address these issues, we have carried out a functional genetic screen in >30 commonly used models of breast cancer to identify genes critical to the growth of specific breast cancer subtypes. In particular, we describe potential new therapeutic targets for PTEN-mutated cancers and for estrogen receptor-positive breast cancers. We also show that large-scale functional profiling allows the classification of breast cancers into subgroups distinct from established subtypes. SIGNIFICANCE: Despite the wealth of molecular profiling data that describe breast tumors and breast tumor cell models, our understanding of the fundamental genetic dependencies in this disease is relatively poor. Using high-throughput RNA interference screening of a series of pharmacologically tractable genes, we have generated comprehensive functional viability profiles for a wide panel of commonly used breast tumor cell models. Analysis of these profiles identifies a series of novel genetic dependencies, including that of PTEN-null breast tumor cells upon mitotic checkpoint kinases, and provides a framework upon which additional dependencies and candidate therapeutic targets may be identified. Cancer Discovery; 1(3);260-73. (C) 2011 AACR.
引用
收藏
页码:260 / 273
页数:14
相关论文
共 44 条
[1]   Genetic Interactions in Cancer Progression and Treatment [J].
Ashworth, Alan ;
Lord, Christopher J. ;
Reis-Filho, Jorge S. .
CELL, 2011, 145 (01) :30-38
[2]   Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 [J].
Baselga, Jose ;
Swain, Sandra M. .
NATURE REVIEWS CANCER, 2009, 9 (07) :463-475
[3]   Analysis of cell-based RNAi screens [J].
Boutros, Michael ;
Bras, Ligia P. ;
Huber, Wolfgang .
GENOME BIOLOGY, 2006, 7 (07)
[4]   53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers [J].
Bouwman, Peter ;
Aly, Amal ;
Escandell, Jose M. ;
Pieterse, Mark ;
Bartkova, Jirina ;
van der Gulden, Hanneke ;
Hiddingh, Sanne ;
Thanasoula, Maria ;
Kulkarni, Atul ;
Yang, Qifeng ;
Haffty, Bruce G. ;
Tommiska, Johanna ;
Blomqvist, Carl ;
Drapkin, Ronny ;
Adams, David J. ;
Nevanlinna, Heli ;
Bartek, Jiri ;
Tarsounas, Madalena ;
Ganesan, Shridar ;
Jonkers, Jos .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2010, 17 (06) :688-U56
[5]   A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers [J].
Carter, Scott L. ;
Eklund, Aron C. ;
Kohane, Isaac S. ;
Harris, Lyndsay N. ;
Szallasi, Zoltan .
NATURE GENETICS, 2006, 38 (09) :1043-1048
[6]   Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase [J].
Colombo, Riccardo ;
Caldarelli, Marina ;
Mennecozzi, Milena ;
Giorgini, Maria Laura ;
Sola, Francesco ;
Cappella, Paolo ;
Perrera, Claudia ;
Depaolini, Stefania Re ;
Rusconi, Luisa ;
Cucchi, Ulisse ;
Avanzi, Nilla ;
Bertrand, Jay Aaron ;
Bossi, Roberto Tiberio ;
Pesenti, Enrico ;
Galvani, Arturo ;
Isacchi, Antonella ;
Colotta, Francesco ;
Donati, Daniele ;
Moll, Juergen .
CANCER RESEARCH, 2010, 70 (24) :10255-10264
[7]   Targeting cell cycle kinases for cancer therapy [J].
de Carcer, Guillermo ;
Perez de Castro, Ignacio ;
Malumbres, Marcos .
CURRENT MEDICINAL CHEMISTRY, 2007, 14 (09) :969-985
[8]  
*F HUTCH CANC RES, BIOC
[9]   Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J].
Farmer, H ;
McCabe, N ;
Lord, CJ ;
Tutt, ANJ ;
Johnson, DA ;
Richardson, TB ;
Santarosa, M ;
Dillon, KJ ;
Hickson, I ;
Knights, C ;
Martin, NMB ;
Jackson, SP ;
Smith, GCM ;
Ashworth, A .
NATURE, 2005, 434 (7035) :917-921
[10]   Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas [J].
Geyer, Felipe C. ;
Weigelt, Britta ;
Natrajan, Rachael ;
Lambros, Maryou B. K. ;
de Blase, Dario ;
Vatcheva, Radost ;
Savage, Kay ;
Mackay, Alan ;
Ashworth, Alan ;
Reis-Filho, Jorge S. .
JOURNAL OF PATHOLOGY, 2010, 220 (05) :562-573